Long-term anti-TNFα therapy for ankylosing spondylitis in two patients with chronic HBV infection

被引：38

作者：

Sakellariou, Grigorios T. ^{[1
]}

Chatzigiannis, Ioannis ^{[1
]}

机构：

[1] St Pauls Hosp, Dept Rheumatol, Thessaloniki 55134, Greece

来源：

CLINICAL RHEUMATOLOGY | 2007年 / 26卷 / 06期

关键词：

ankylosing spondylitis; etanercept; hepatitis B; infliximab;

D O I：

10.1007/s10067-006-0392-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anti-TNF alpha therapy for rheumatic diseases appears to be safe in patients with chronic hepatitis C. However, the administration of anti-TNF alpha agents without initiation of prophylactic antiviral therapy (lamivudine 100 mg/day) in patients with chronic HBV infection results in exacerbation of liver disease. In this report, we describe our experience of long-term anti-TNF alpha therapy for ankylosing spondylitis in two inactive HBsAg carriers without preemptive antiviral treatment.

引用

页码：950 / 952

页数：3

共 11 条

[1] Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection [J].

Calabrese, LH ;

Zein, N ;

Vassilopoulos, D .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 :18-24

[2] Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients:: need for primary prophylaxis [J].

Esteve, M ;

Saro, C ;

González-Huix, F ;

Suarez, F ;

Forné, M ;

Viver, JM .

GUT, 2004, 53 (09) :1363-1365

[3] Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 [J].

Furst, DE ;

Breedveld, FC ;

Kalden, JR ;

Smolen, JS ;

Burmester, GR ;

Bijlsma, JWJ ;

Dougados, M ;

Emery, P ;

Keystone, EC ;

Klareskog, L ;

Mease, PJ .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 :2-14

[4] Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection [J].

Garcia-Sánchez, MD ;

Gómez-Camacho, F ;

Poyato-González, A ;

Iglesias-Flores, EM ;

de Dios-Vega, JF ;

Sancho-Zapatero, R .

INFLAMMATORY BOWEL DISEASES, 2004, 10 (05) :701-702

[5] Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes [J].

Guidotti, LG ;

Ishikawa, T ;

Hobbs, MV ;

Matzke, B ;

Schreiber, R ;

Chisari, FV .

IMMUNITY, 1996, 4 (01) :25-36

[6] Subfulminant hepatitis B after infliximab in Crohn's disease: Need for HBV-screening? [J].

Millonig, Gunda ;

Kern, Michaela ;

Ludwiczek, Othmar ;

Nachbaur, Karin ;

Vogel, Wolfgang .

WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (06) :974-976

[7]

Oniankitan O, 2004, J RHEUMATOL, V31, P107

[8] Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate [J].

Ostuni, P ;

Botsios, C ;

Punzi, L ;

Sfriso, P ;

Todesco, S .

ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (07) :686-687

[9]

ROUX CH, 2006, IN PRESS RHEUMATOLOG

[10] Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B [J].

Ueno, Y ;

Tanaka, S ;

Shimamoto, M ;

Miyanaka, Y ;

Hiyama, T ;

Ito, M ;

Kitadai, Y ;

Yoshihara, M ;

Sumii, M ;

Chayama, K .

DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (01) :163-166

← 1 2 →